I
t has been nearly 15 years since the US Food and Drug Administration (FDA) approved the use of recombinant human bone morphogenetic protein (rhBMP) for use in combination with single-level anterior lumbar fusion surgery. Although the use of rhBMP has risen steadily since the time of its approval, 1 there is controversy with respect to its safety. In particular, there is a concern that rhBMP may contribute to tumorigenesis. The results of two recent metaanalyses of randomized trials suggest a two to three fold increase in cancer risk (all sites combined) among rhBMP recipients, 2, 3 but the interpretation of these data is limited by: the relatively small number of subjects and short duration of follow-up in the underlying trials and the likely incomplete ascertainment of cancer incidence.
We evaluated the experience of patients to whom rhBMP had been administered through the use of data sets obtained from the Washington State Comprehensive Hospital Abstract Reporting System (CHARS), the Washington State Cancer Registry (WSCR), and state of Washington death certificates to study the possible association between rhBMP and cancer risk.
MATERIALS AND METHODS

Data Sources and Linkage
We used four databases from the State of Washington for the present study: The CHARS, the WSCR, The Washington State Department of Health's Vital Records, and the Washington State Department of Licensing (DOL).
CHARS is the Washington State's registry of hospital discharges maintained by the Washington State Department of Health. It contains demographic information, admission and discharge details, and ICD-9-CM diagnosis and procedure (CPT) codes for all inpatient discharges from nonfederal hospitals (public and private) in Washington State. The Washington State Department of Health receives data from the hospitals and ensures verification of the data set elements set forth by State Administrative Code. 4 The WSCR was established in 1991 with data collection starting January 1, 1992, as a result of legislation making cancer a reportable condition in the State of Washington. Reportable cancers include any malignant neoplasms except for basal and squamous cell carcinoma of the skin, and cancer in situ of the uterine cervix. The North American Association of Central Cancer Registries (NAACCR) certifies central cancer registries based on case completeness, timeliness of reporting, and quality of data. WSCR has been recognized with NAACCR certification each year since its inception in 1997.
The Washington State Department of Health's Vital Records contains information on date and cause of death from death certificates for residents in the State of Washington. The DOL provides information on residency through state driver license renewals.
Through an hierarchical deterministic program we linked CHARS to the cancer registry, state death certificates, and DOL data using last name, first name, sex, zip code, date of birth, partial social security number, last name initials, and first name initials. As in a probabilistic linkage, certain variables (e.g., last name, first name, zip code) were weighted to give more credence to less frequent values. For CHARS before 2007, only name initials are available. Beginning in 2007, full names and a partial SSN are available. For CHARS entries with only name initials, those initials, date of birth, and sex were required to be exact matches. Although patient identifiers were used to link the data sets, a deidentified data set was used for the analysis. The present study was approved by the Washington State institutional review board.
Study Population
We identified adults ages 21 years or older who underwent spine fusion (procedure codes 81.00-81.08) or refusion (81.30-81.39) for degenerative spine disease between January 1, 2002 and December 31, 2010. The start year was 2002 because it was the first year rhBMP received FDA approval. From these patients we identified all patients who received rhBMP (procedure code 84.52) as part of their treatment. We then selected a comparison group via computer programming, matching each patient receiving rhBMP with three patients not receiving rhBMP using age (within 2 years), sex, and year of treatment. We excluded patients receiving spine fusion as a result of vertebral fractures or infection, and those with a diagnosis of cancer before or at the index procedure as identified from the WSCR or CHARS.
Outcomes
The primary outcome was the first diagnosis of all reportable cancers except nonmelanotic skin cancers identified in the WSCR before December 31, 2010. We did a secondary analysis adding cases in which cancer was listed as a cause of death on the death certificate, even though the person's malignancy was not identified in the records of the WSCR. In such (uncommon) instances, we used the date of death as the date of diagnosis.
Time at risk for all patients started on the day of admission for the index spine fusion or refusion. To calculate the cancer incidence rate, time at risk continued until cancer was diagnosed or until follow-up was censored, which occurred upon death or at the end of the study period. To calculate the mortality rate from all causes and the mortality rate with cancer as the underlying cause, time at risk continued until the patient died or until the end of the study period. Time at risk was counted in days and converted to person years at risk.
Although patients likely resided in Washington at the time of the index fusion, some may have out-migrated after surgery and not been identified if cancer developed while residing out of the state. We used the linked DOL data to ascertain residency status of patients during the study period. Known state residents included those with a state driver's license renewal within 5 years of the index procedure. We tested the assumption that any out-migration would be nondifferential between the rhBMP and nonrhBMP2 groups. We did this by repeating the cancer rate analysis of patients who, based on these criteria, were state residents within 5 years of a cancer diagnosis and compared the results to our primary analysis. The primary analysis included all patients with and without a 5-year driver's license renewal.
Statistical Methods
Survival analysis was performed to compare the frequency of outcomes along with the timing of their occurrences. Calendar dates of events and censoring times were converted to the number of days from initial surgery. Incidence rates (hazards) were computed by taking the ratio of the number of events and total time at risk. Unadjusted and adjusted hazard ratios (HRs) and their 95% confidence intervals (CIs) were calculated assuming a Cox proportional hazard regression model. We adjusted for the site of surgery (lumbar vs. cervical) as this differed in frequency between the two treatment groups. The ratio between the observed and expected numbers of cancer (the standardized incidence ratio) for the more common cancers in the rhBMP group was calculated with 95% CIs, assuming a Poisson distribution. Analyses were performed using Stata software, version 12.0 (College Station, TX).
RESULTS
Patient Characteristics
There were 4257 patients who received spine fusion or refusion with rhBMP during 2002 through 2010. We selected 12,748 patients who received spine fusion without rhBMP during the same period as the comparison group. Three patients receiving rhBMP had spine fusion for a spine infection and seven as a result of trauma. In the comparison group, 46 received spine fusion for a spine infection and 31 as a result of trauma. These were excluded. We also excluded four patients who had no diagnosis (one in the rhBMP group, three in the non-rhBMP group) leaving us with 4246 fusion patients who received rhBMP and 12,668 who did not ( Figure 1 ). The mean age of the study population was 55.4 years, and 42% were men. The average follow-up was 4.7 years. Patients having spine fusion with or without rhBMP were similar with respect to age, sex, primary diagnosis, surgical method (anterior, posterior, combined), timing of fusion (primary or revision), and year of fusion. There was a higher proportion of patients receiving lumbosacral fusion in the rhBMP group compared with those not receiving rhBMP, 84% versus 41% (Table 1) .
Cancer Incidence
During the study period, 445 patients received a diagnosis of cancer as reported by the cancer registry: 117 (2.76% of 4246) in the rhBMP group and 328 (2.59% of 12,668) in the no rhBMP group.
The incidence rate was similar between the two groups: 9.5 per 1000 person years in the rhBMP group and 8.9 per 1000 person years in the no rhBMP group (HR, 1.07; 95% CI, 0.87-1.32; Table 2 ). In the Cox regression model controlling for the site of fusion, the adjusted HR was 0.93 (95% CI, 0.74-1.16) (Figure 2) . The results were similar when we added the cancer patients identified from the death certificate but not found in the WSCR (Table 2 ). When the analysis was restricted to patients categorized as residents from the DOL database, the HR was 1.05 (95% CI, 0.86-1.30).
There were no differences in the rate of cancer between the rhBMP and no rhBMP groups based on site of fusion (cervical or lumbar) or surgical method (anterior, posterior, or combined anterior and posterior) ( Table 3 ). There were no differences between groups when stratified by duration of follow-up (Table 4) .
The observed number of cancers in the rhBMP group were higher than the expected number of cancers of the corpus uteri (standardized incidence ratio [SIR], 2.3; 95% CI, 0.5-10.1; P ¼ 0.314), the oral cavity (SIR, 9.0; 95% CI, 0.9-86.5; P ¼ 0.055), and the liver (SIR, 4.5; 95% CI, 0.8-26.9; P ¼ 0.119) ( Table 5 ). Each of these observed associations was, however, within the limits of chance given no true difference in risk.
Mortality Due to Cancer
Mortality due to cancer was similar between groups: 1.8 compared with 1.7 per 1000 person years in the rhBMP and no rhBMP group, respectively (HR, 1.08; 95% CI, 0.75-1.57) ( Table 2 ). Controlling for the site of fusion, the adjusted HR was 1.11 (95% CI, 0.74-1.66). The results were similar when we added the cancer patients identified from the death certificate but not found in the WSCR (Table 2) .
DISCUSSION
Historically, spinal arthrodesis has relied on autogenous bone grafting to stimulate fusion. The source of autograft is typically obtained from either the anterior or posterior iliac crest, or when available, from locally harvested bone during a decompression. Autograft is, however, not always adequate in volume or quality, and can be associated with surgical morbidity. Accordingly, bone graft extenders and substitutes have been developed to enhance or replace autograft. rhBMP-2 introduced in 2002, has become one of the most commonly used bone graft substitutes. Although approved for use in anterior lumbar interbody fusion, the application of rhBMP expanded at an alarming rate in offlabel use, both in location and dosage. Cahill et al In 2011, Carragee 10 compared the conclusions regarding the safety and efficacy of industry-sponsored trials of rhBMP-2 published in the peer-reviewed literature the data available from the US FDA data summaries. With respect to cancer risk, the FDA recommended post-market surveillance studies, citing there was a higher number of cancers in the investigational group as compared to the control group that warranted further investigation. 11 In 2012, DeVine et al 12 independently reviewed the cancer risk of rhBMP2 use in spine fusion as published in the literature to date and in the publically available FDA data summaries, concluding that the cancer risk may be dose dependent based on data from off-label use of rhBMP for posterolateral fusions in three randomized controlled trials and one retrospective cohort study. Interestingly, the listed cancer types appeared incidental and did not fit a pattern or type of cancer. Nor were they of the systemic or disseminated variants one might be most concerned about with a growth-enhancing substance such as rhBMP. The wide distribution of isolated and localized cancers reported included basal cell, squamous cell, prostate, and ocular cancers. In 2013, The Yale University Open Data Access project resulted in two meta-analyses of randomized trials suggesting a two to three fold increase in cancer risk (all sites combined) among rhBMP recipients, 2, 3 The meta-analysis by Simmonds et al 3 reported 20 of 694 cancer cases in the study group compared with 8 of 608 in the control group. The meta-analysis by Fu et al 2 reported 18 of 633 cancer cases in the study group versus 6 of 817 in the control group at 24 months, and 20 of 483 cancer cases in the control group compared with 11 of 700 in the control group at 48 months. The event rates were, however, low, the duration of follow-up was short, and the cancers were 
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The Risk of Cancer With the Use of rhBMP in Spine Fusion Dettori et al heterogeneous, making definitive conclusions regarding cancer risk inconclusive. Therefore, attempts have been made to study larger patient populations with longer follow-up periods retrospectively. Although several limitations exist with this type of analysis, the potential to look at large patient populations with longer follow-up and off-label rhBMP use, both in application (anterior and posterior cervical, posterior lumbar) and dosing, could provide some insight into the potential for cancer risk.
A large cohort study 13 has evaluated the potential effect of rhBMP on risk of malignant neoplasm in 146,278 Medicare beneficiaries who underwent lumbar fusion surgery from October 2003 to December 2008. A claim for rhBMP (ICD-9-CM 84.52) on the same day as fusion surgery was used a surrogate for exposure. A diagnosis of malignant neoplasm after surgery required two or more ICD-9-CM diagnosis codes and at least one code consistent with cancer therapy. After an average follow-up of 4.7 years, 17% of the non-rhBMP (n ¼ 21 079) and 15.4% (n ¼ 3402) of the rhBMP group had a new cancer diagnosis. After adjusting for potential confounding factors in a multivariable proportional hazards model, there was no appreciable association with cancer risk (all types combined) (HR, 0.99; 95% CI, 0.95-1.02) or with the incidence of any particular form of cancer. Somewhat smaller studies utilizing the MarketScan database (Truven Health Analytics) 14, 15 that have analyzed the experience of recipients of rhBMP similarly have failed to identify an altered risk of cancer.
Although in our study population there were several-fold increases in risk of cancers of the corpus uteri, oral cavity, and liver associated with receipt of rhBMP, these were based on but three cases each, and the observed excess risk was statistically compatible with there being no true increase. In the far-larger study based on Medicare beneficiaries 13 there was no hint of an increased incidence of uterine corpus, oral cavity, or liver cancer. There are limitations to using administrative databases to answer clinical questions. The possibility of misclassification by improper coding cannot be excluded. It is likely that any misclassification of diagnoses or treatment interventions from the CHARS database would be nondifferential with regard to the comparison groups. These data also lack such specificity as disease severity and level of spinal operation. Furthermore, data available were insufficient to determine the effect of rhBMP-2 dose on estimates of cancer risk. It is possible that those patients who received BMP were more severe cases; however, it is unclear how this would affect the BMP-cancer association. Our sample had a smaller proportion of patients receiving rhBMP-2 compared with no rhBMP-2 administration in cervical spine fusion.
This discrepancy likely reflects the more limited clinical use of the biologic in the cervical spine given safety concerns with respect to airway complications. Nonetheless, we were able to identify the anatomical region of the operation (i.e., cervical vs. lumbar fusion) and adjust for this in our analysis. Furthermore, the WSCR cancer registry has been certified by the NAACCR each year because its inception based on its case completeness, timeliness of reporting, and quality of the data; as such, any cancer misclassifications would also likely be nondifferential. Administrative data are also susceptible to confounding factors that may attenuate a causal inference. We matched on the factors we felt have the greatest association with cancer incidence, which will account for some of this potential confounding. By excluding patients receiving spinal fusion as a result of vertebral fractures or infection, and those with a diagnosis of cancer before or at the index procedure, we have accounted for additional potential confounding. Patients included in the study cohort may have outmigrated from Washington State after undergoing spinal fusion. This may have an effect on the rates of cancer that we observed. We attempted to account for this by linking our data to DOL data. We considered known residents as those with a state license renewal within 5 years of the index procedure. We compared our cancer rate analysis on all patients in our study cohort with those who were state residents within 5 years of cancer diagnosis and detected little difference in the effect of BMP on cancer suggesting any effect of out-migration would be nondifferential.
In our view, the largely negative results regarding rhBMP administration and cancer incidence that have been obtained in the various cohort studies are more compelling than the corresponding positive results obtained in the randomized trials: the former were large and were able to address potential confounding to a considerable degree, 
The Risk of Cancer With the Use of rhBMP in Spine Fusion Dettori et al whereas the likely incomplete ascertainment of cancer cases and relatively small size of the trials hinders the interpretation of the results of these studies. Nonetheless, an important limitation of all studies (whether randomized or not) of rhBMP and cancer that have been conducted to date, including ours, is their relatively limited duration of follow-up of recipients of this treatment. Although the collective results available are somewhat reassuring, the examination of cancer incidence in patients who have received rhBMP must continue beyond just the first several years to adequately assess the potential of rhBMP to influence the occurrence of one or more types of malignancy.
Key Points
There was no increase in overall cancer incidence identified from the WSCR among spine fusion patients receiving rhBMP. In our view, the largely negative results regarding rhBMP administration and cancer incidence that have been obtained in the various cohort studies are more compelling than the corresponding positive results obtained in the randomized trials: the former were large and were able to address potential confounding to a considerable degree, whereas the likely incomplete ascertainment of cancer cases and relatively small size of the randomized trials hinders the interpretation of the results of these studies. An important limitation of the present and other studies of rhBMP and cancer is the relatively limited duration of follow-up. The examination of cancer incidence following rhBMP administration must continue beyond just the first several years to adequately assess the potential of rhBMP to influence the occurrence of one or more types of malignancy. 
